Literature DB >> 1819746

Antitumor activity of Ilmofosine (BM 41.440) in the 3Lewis-lung carcinoma model.

D B Herrmann1, H G Opitz, P G Munder.   

Abstract

Ilmofosine (1-hexadecylthio-2-methoxymethyl-1,3-propanediol-phosphocholine, BM 41.440) is a thioether phospholipid with cytostatic/cytotoxic properties. The antineoplastic activity of this compound was investigated in vivo in the 3Lewis-lung carcinoma system. 3Lewis lung tumor-bearing C57Bl/6 mice were treated with 0.625 to 40 mg Ilmofosine/kg per day p.o. either from days 1 to 9 or from days 11 to 28 after intrafoot-pad tumor cell inoculation. Ilmofosine caused a significant dose-related response on tumor growth and metastases, expressed in terms of tumor diameter, tumor weight, survival time and number of metastases-free animals as compared to sham-treated and positive (cyclophosphamide) controls. The results suggest that direct cytostatic/cytotoxic effects, rather than immune-modulatory mechanisms, preferentially contribute to the antitumor activity of Ilmofosine in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1819746     DOI: 10.1007/BF02536581

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  37 in total

1.  Selective destruction of human leukemic cells by alkyl-lysophospholipids.

Authors:  R Andreesen; M Modolell; H U Weltzien; H Eibl; H H Common; G W Löhr; P G Munder
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

2.  Effects of thioether phospholipid BM 41.440 on protein kinase C and phorbol ester-induced differentiation of human leukemia HL60 and KG-1 cells.

Authors:  M Shoji; R L Raynor; W E Berdel; W R Vogler; J F Kuo
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

3.  Biologic characterization of the subcutaneously implanted Lewis lung tumor.

Authors:  J G Mayo
Journal:  Cancer Chemother Rep 2       Date:  1972-11

4.  Histopathology of the host response to Lewis lung carcinoma: modulation by pyran.

Authors:  M J Snodgrass; P S Morahan; A M Kaplan
Journal:  J Natl Cancer Inst       Date:  1975-08       Impact factor: 13.506

5.  Effect of lysolecithin and analogs on mouse ascites tumors.

Authors:  G S Tarnowski; I M Mountain; C C Stock; P G Munder; H U Weltzien; O Westphal
Journal:  Cancer Res       Date:  1978-02       Impact factor: 12.701

6.  Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids.

Authors:  M Modolell; R Andreesen; W Pahlke; U Brugger; P G Munder
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

7.  Pharmacokinetics of the thioether phospholipid analogue BM 41.440 in rats.

Authors:  D B Herrmann; E Besenfelder; U Bicker; W Pahlke; E Böhm
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

8.  Lack of correlation between cytotoxicity of agonists and antagonists of platelet activating factor [paf-acether] in neoplastic cells and modulation of [3H]-paf-acether binding to platelets from humans in vitro.

Authors:  W E Berdel; R Korth; A Reichert; W J Houlihan; U Bicker; H Nomura; W R Vogler; J Benveniste; J Rastetter
Journal:  Anticancer Res       Date:  1987 Nov-Dec       Impact factor: 2.480

9.  Cytotoxic ether phospholipids. Different affinities to lysophosphocholine acyltransferases in sensitive and resistant cells.

Authors:  D B Herrmann; H A Neumann
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

10.  Lewis lung carcinoma in mice as an experimental therapy model. II. The effect of BCNU, cyclophosphamide and/or surgery treatment on early and advanced tumor in mice.

Authors:  W Budzyński
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1982       Impact factor: 4.291

View more
  2 in total

1.  Phase I trial of ilmofosine as a 24 hour infusion weekly.

Authors:  M von Mehren; B J Giantonio; C McAleer; R Schilder; J McPhillips; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

2.  A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma.

Authors:  P V Woolley; C J Schultz; G I Rodriguez; R A Gams; K W Rowe; M L Dadey; D D Von Hoff; J J McPhillips
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.